about
P1343
Androgen regulation of the human FERM domain encoding gene EHM2 in a cell model of steroid-induced differentiationNear IR heptamethine cyanine dye-mediated cancer imagingBeta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cellsExpression of P-cadherin identifies prostate-specific-antigen-negative cells in epithelial tissues of male sexual accessory organs and in prostatic carcinomas. Implications for prostate cancer biology.Androgen and retinoic acid interaction in LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptorMembrane androgen binding sites are preferentially expressed in human prostate carcinoma cellsProstate cancer metastasis: roles of recruitment and reprogramming, cell signal network and three-dimensional growth characteristicsAndrogen receptor and prostate cancer stem cells: biological mechanisms and clinical implicationsAndrogen receptor specifically interacts with a novel p21-activated kinase, PAK6Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cellsLoss of heterozygosity and lack of mutations of the XPG/ERCC5 DNA repair gene at 13q33 in prostate cancer.Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel.Muscadine grape skin extract reverts snail-mediated epithelial mesenchymal transition via superoxide species in human prostate cancer cells.Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.Monoamine oxidase A mediates prostate tumorigenesis and cancer metastasis.Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.The desmosomal armadillo protein plakoglobin regulates prostate cancer cell adhesion and motility through vitronectin-dependent Src signalingThe role of epithelial plasticity in prostate cancer dissemination and treatment resistanceBone Metastasis of Prostate Cancer Can Be Therapeutically Targeted at the TBX2-WNT Signaling Axis.Inhibition of both EGFR and IGF1R sensitized prostate cancer cells to radiation by synergistic suppression of DNA homologous recombination repairAndrogens as therapy for androgen receptor-positive castration-resistant prostate cancer.Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.In vitro and in vivo model systems used in prostate cancer research.Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancerSecreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer.Metastasis initiating cells in primary prostate cancer tissues from transurethral resection of the prostate (TURP) predicts castration-resistant progression and survival of prostate cancer patientsEpidermal growth factor promotes protein degradation of epithelial protein lost in neoplasm (EPLIN), a putative metastasis suppressor, during epithelial-mesenchymal transitionMouse models for studying prostate cancer bone metastasis.Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells.Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling.Molecular profiling of single cancer cells and clinical tissue specimens with semiconductor quantum dotsEricifolin: a novel antitumor compound from allspice that silences androgen receptor in prostate cancer.Tumor-stroma co-evolution in prostate cancer progression and metastasis.Androgen receptor differentially regulates the proliferation of prostatic epithelial cells in vitro and in vivo.Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies.Is DHT Production by 5α-Reductase Friend or Foe in Prostate Cancer?Phorbol ester phorbol-12-myristate-13-acetate induces epithelial to mesenchymal transition in human prostate cancer ARCaPE cells.Progressive epithelial to mesenchymal transitions in ARCaP E prostate cancer cells during xenograft tumor formation and metastasis.Regulation of prostate cancer progression by the tumor microenvironment.Induction of integrin α2 in a highly bone metastatic human prostate cancer cell line: roles of RANKL and AR under three-dimensional suspension culture.
P2860
Q24296691-9D01E2DB-C9AC-4F83-B58B-90DA8B6E28A7Q24616262-B2FB0B92-906C-4377-A00E-1F173B6DFB3FQ24631263-08B263D7-3A9E-428E-B00B-42EE55655177Q24678580-50B503AA-2662-4B6E-A7E0-BABA5B72E282Q24796211-3FE8E242-9431-4DB4-940D-85AEFEBA4121Q24800710-3A4B8DF2-6DC2-4E43-949E-1EF573C20FD3Q26773613-8A9C950F-8DC0-4A04-9E63-B18FE5FBAB2BQ26797063-FF1880CC-436C-4383-852E-8D53E9535C89Q28208123-DEC46E68-F93B-4FE2-814C-6922B562E195Q28209528-E1BE4316-5625-4A0A-9D34-FF1DCCA6398BQ30304332-44D0055F-D0A4-4986-AFC1-2F93353D8F45Q30307433-E98E1AA3-67DA-461C-9C08-D2B48772713AQ31153800-76A0F978-F0EF-44DF-9A2C-04CBF563CA4EQ33645250-191A48A9-CE73-458F-A6CC-F677D7AE138FQ33808309-5B73A3F9-5155-45F7-A952-31A8ADB1BA39Q34124650-BAA18899-0F0F-476F-81E2-98DE0AAC3F48Q34364523-F08A1655-4A2D-443B-B6F7-F57DE38454BFQ34505037-09836A6B-916C-41F3-A20E-B62D514475ACQ34549787-73B141AA-8AB9-4AB9-885A-0C24B6FF2F8BQ34946047-B28BFC61-F51C-4EF4-945C-8DCD3BAA9076Q35207110-E2CE8D95-48F4-4D52-9E96-815ECA5EC25BQ35434843-1BA81A29-F326-4367-8803-6AFDC92FA985Q35806390-ABE99D87-C729-4FED-92EB-A9E8C18F41E1Q36172754-9776B902-D67D-43AA-AAE9-B265F5BF9FC7Q36368188-F0853192-2F1D-494B-8279-B9774772D7D7Q36530753-C6A8F2C5-59BA-4F66-8848-15683753811FQ36543668-C893213C-0F32-42A9-BFC0-FFD5346F2A7BQ36590497-6F20E22A-CA42-4F0E-B5FF-C4356903CF84Q36617757-DE693C50-87F2-4232-AD11-078169FE040FQ36739768-6FF0E6AF-46CB-4B95-810A-D434E55646A9Q36920341-B91885BC-C48D-446A-815F-648C0497B803Q37065345-C55B0277-3F45-446D-B493-BD3D94518D3FQ37641468-A3121391-37B0-4A55-A4DE-3CFF77471844Q37688544-82513DE5-59F4-46C0-BD6C-BD7C9A1EA65EQ37800061-C95AB7FA-EDBF-4AD7-A3C7-8F607F779835Q38256395-27A2EAB7-8077-413D-B7AD-5765818A74C6Q38570239-5DC18EBC-E2A1-49E3-AF33-556D1BADF69AQ38570292-B881F75E-2AEA-4A40-A042-BB6BAB3FE59CQ38717262-68A141FF-1E91-43BD-A704-048464F49749Q38958606-864EA27D-49E3-40F1-A9EC-345E74007272
P2860
description
1996 nî lūn-bûn
@nan
1996 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Androgen-repressed phenotype in human prostate cancer.
@ast
Androgen-repressed phenotype in human prostate cancer.
@en
type
label
Androgen-repressed phenotype in human prostate cancer.
@ast
Androgen-repressed phenotype in human prostate cancer.
@en
prefLabel
Androgen-repressed phenotype in human prostate cancer.
@ast
Androgen-repressed phenotype in human prostate cancer.
@en
P2093
P2860
P356
P1476
Androgen-repressed phenotype in human prostate cancer.
@en
P2093
S J Pathak
P2860
P304
15152-15157
P356
10.1073/PNAS.93.26.15152
P407
P4510
P577
1996-12-01T00:00:00Z